Test Performance and Potential Clinical Utility of the GenMark Dx ePlex Blood Culture Identification Gram-Negative...

Area of Science:

• Clinical microbiology
• Infectious diseases
• Diagnostic technology

Background:

• Bloodstream infections (BSIs) require timely and accurate pathogen identification for effective treatment.
• Current methods for identifying Gram-negative bacteria in blood cultures can be time-consuming.
• Antimicrobial resistance necessitates rapid diagnostics to guide appropriate therapy.

Purpose of the Study:

• To evaluate the performance and clinical utility of the ePlex blood culture identification Gram-negative (BCID-GN) panel.
• To compare the ePlex BCID-GN panel with matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry and conventional antimicrobial susceptibility testing.
• To assess the impact of the ePlex BCID-GN panel on antibiotic prescribing and patient care.

Main Methods:

• The study evaluated the ePlex BCID-GN panel against MALDI-TOF MS and antimicrobial susceptibility testing using bacterial isolates from blood cultures.
• Performance metrics included percent agreement, time to result, and identification of resistance genes.
• A chart review of 98 patients was conducted to assess clinical utility, including antibiotic discontinuation and therapy optimization.

Main Results:

• The ePlex BCID-GN panel correctly identified 98.1% of Gram-negative bacteria identified by MALDI-TOF MS.
• Results were obtained 26.7 hours earlier on average compared to conventional methods.
• Negative pan-Gram-positive markers facilitated the discontinuation of Gram-positive antibiotic coverage in 64.3% of cases, 26.2 hours earlier.
• Early detection of resistance mechanisms (e.g., CTX-M) and specific resistant organisms (e.g., Stenotrophomonas maltophilia, Acinetobacter baumannii) enabled antimicrobial therapy optimization in 6.1% of patients.

Conclusions:

• The GenMark Dx ePlex system provides rapid identification of Gram-negative bacteria in blood cultures, improving time to diagnosis.
• The panel's ability to rule out Gram-positive bacteria supports earlier de-escalation of antibiotic therapy.
• Early detection of antimicrobial resistance and specific pathogens allows for timely optimization of patient treatment, enhancing care.